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Tumor-produced extracellular matrix (ECM) proteins can be key elements in tumor growth and metastasis.
Transforming growth factor beta–inducible (TGFBI) protein is a secreted ECM component that can have dual
function in cancer, acting as tumor suppressor or promoter. Although TGFBI is expressed in human melanoma
cells, the exact role it might have in melanoma metastasis remains elusive. Assessing the expression and secretion
of TGFBI, we show that human metastatic melanomas express and secrete significantly higher amounts of TGFBI,
compared with nevus lesions and primary melanoma tumors. Intravenous injection of highly metastatic human
melanoma cells expressing shRNA that targets TGFBI assigns a critical role for TGFBI in the formation of
melanoma distal metastases in nude mice. In vivo assays demonstrate that TGFBI silencing does not interfere with
melanoma cells’ dissemination to distal sites but rather with their proliferation and outgrowth within new
microenvironment. In line, TGFBI silencing increases melanoma cells motility/invasion/extravasation in vitro but
interferes with their progression through the cell cycle, drastically reducing their proliferation. Furthermore,
we show that TGFBI is a regulator of cyclins and cyclin-dependent kinases in melanoma. Collectively, our
data describe a mechanism of melanoma metastatic outgrowth via promotion of growth/survival by the ECM
protein TGFBI.
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INTRODUCTION
Melanomas are highly aggressive malignancies that frequently
disseminate, remaining therefore an enormous clinical chal-
lenge. The factors involved in their metastatic outgrowth are not
yet fully explored, and a deeper understanding of such factors
should lead to more effective therapies (Spano et al., 2012).
The extracellular matrix (ECM) proteins, compromising
tumor microenvironment, can be key elements in tumor
growth and metastasis (Wong and Rustgi, 2013). They can
act as regulators of survival, proliferation, differentiation, and
cell migration/invasion. Melanoma cells often modify their
microenvironment through secretion of specific ECM proteins
and ECM-modifying proteases to be more permissive for their
growth and dissemination (Botti et al., 2012).
The transforming growth factor beta (TGFb)-induced protein
(TGFBI) is a secreted ECM protein mainly expressed in
fibroblasts, keratinocytes, and muscle cells. It can associate
with several ECM proteins and function in many cell types as a
linker protein connecting various matrix molecules to each
other facilitating cell–ECM interactions (Thapa et al., 2007).
In cancer, the expression and functional role of TGFBI has
been controversial. TGFBI was found increased in various
tumors (Sasaki et al., 2002; Ma et al., 2008; Lin et al., 2010;
Turtoi et al., 2011; Ma et al., 2012) whereas downregulated in
others (Kang et al., 2010; Kaiser et al., 2013). However, recent
findings in ovarian cancer have indicated that TGFBI could
probably has dual function acting as tumor suppressor or
promoter (Ween et al., 2012). In melanoma, while microarray
analysis showed increased expression of TGFBI in cells from
metastatic and vertical growth phases (Hoek, 2007; Nummela
et al., 2012), TGFBI was also identified as decitabine-induced
gene through epigenetic histone modification (Halaban et al.,
2009). We found that TGFBI is upregulated in multicellular
melanoma spheroids, which possess high metastatic potential
(Ramgolam et al., 2011). These studies have been supported
by recent findings showing that TGFBI is located in fibrillar
structures in human melanoma metastases, and knockdown
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of TGFBI expression in melanoma cells impaired tumor
formation and vertical growth phase (Nummela et al., 2012).
However, the exact role of TGFBI in melanoma metastasis
remains incompletely understood.
In this study, we developed a metastasis model based on
intravenous injection of highly metastatic 1205Lu human mel-
anoma in nude mice and assessed the effect of silencing TGFBI
on melanoma cells’ dissemination and metastases formation.
Our results show that lack of TGFBI secretion by metastatic
melanomas results in drastic reduction in their distal metastatic
outgrowth mainly by disturbing their cell cycle progression likely
with defects in G1/S transition and S phase regulation.
RESULTS
Metastatic melanomas produce large amounts of TGFBI
We first compared the mRNA expression in biopsies from
human nevi lesions, primary skin and metastatic melanomas.
Primary skin melanomas showed little variations in TGFBI level
compared with benign nevi (1- to 2-fold induction). TGFBI
expression levels were higher in metastatic melanomas than
in benign lesions or primary melanomas (ranging from 1.5- to
9.5-fold induction) (Figure 1a). This scattered variation in
TGFBI mRNA expression was not tissue specific, but we could
clearly define two groups of metastatic melanomas, a low (1-
to 2.5-fold induction) and a high (2.7- to 9.8-fold induction)
expressing group. To see the potential relevance of these
findings, we then performed TGFBI immunostaining in human
nevi lesions, primary melanomas, and skin, liver and lymph
node metastases. Despite heterogeneity in the expression level,
nevi lesions showed non- or very faint TGFBI staining
(Figure 1b). In contrast, TGFBI was detected around melanoma
cells in primary and metastatic lesions (Figure 1b), which is in
accordance with being a secreted ECM and with its reported
localization within fibrillar structures surrounding melanoma
cells (Nummela et al., 2012). Compared with nevus lesions
and primary tumors, TGFBI staining was more intense in
metastases, suggesting that metastatic melanoma cells secrete
higher amounts of TGFBI than primary melanomas.
To verify the possibility that TGFBI was secreted by
melanoma cells and not surrounding cells, we compared the
secretion of TGFBI in different cell lines derived from human
primary melanomas (WM983A and WM793) or their respec-
tive metastatic counterparts from the same patients (WM983B,
1205Lu). All melanoma cell lines secrete large amounts of
TGFBI, but secretion levels were significantly higher in
metastatic ones (Figure 1c).
TGFBI is required for melanoma metastatic outgrowth
The above findings suggest that the secretion of TGFBI by
melanoma cells might have a role in melanoma metastasis,
therefore we developed a metastasis model and assessed the
effect of silencing TGFBI. Metastatic melanoma cells were
engineered to express either a non-target shRNA (CTRL-GFP
(green fluorescent protein)-shRNA-1205Lu) or shRNA that
targets TGFBI (GFP-TGFBI-shRNA-1205Lu) (Supplementary
Figure S1 online) and were injected into the retro-orbital
venous sinus of immunodeficient mice. All mice that received
TGFBI-producing CTRL-shRNA-1205Lu cells (16 mice)
showed significant weight loss 3 weeks post injection
(Figure 2a). Three out of the 16 recipient mice died very early
(day 15), and the remaining mice were moribund 15–47 days
post injection (Figure 2b). In contrast, mice that received TGFBI-
shRNA-1205Lu cells (15 mice) producing very low levels of
TGFBI (Supplementary Figure S1b and c online) did not show
major changes of their weight (Figure 2a), showed delay in
disease development, and increase in disease-free survival (6/15
TGFBI-shRNA-1205Lu challenged mice) (Figure 2b).
CTRL-shRNA-1205Lu group (10/10) developed proximal
tumor metastases while only 9/15 mice that received TGFBI-
shRNA-1205Lu cells developed proximal metastases
(Figure 2c), which were remarkably smaller than those of
the CTRL-shRNA-1205Lu challenged group. Examination of
the lung showed high incidence of distal metastases foci in
CTRL-shRNA group (10/10), whereas none of the mice in the
TGFBI-shRNA group developed distal metastases (Figure 2c).
In line, the mitotic figures were more abundant in CTRL-
shRNA compared with the TGFBI-shRNA group (Figure 2d).
Examination of draining and non-draining lymph nodes as
well as several other organs (data not shown) did not reveal
any other metastases development both in CTRL or TGFBI
knockdown tumor-challenged mice. Immunohistochemical
analyses showed intense TGFBI staining around infiltrating
tumor cells in proximal and distal lung and ovary metastases
in CTRL-shRNA-1205Lu-induced tumors (Figure 2e). In con-
trast, TGFBI-shRNA-1205Lu-induced tumors showed either
faint TGFBI staining of the proximal metastasis and no or
only background staining level of lung and ovary tissues.
Thus, TGFBI is critical for distal metastases development in
melanomas.
TGFBI knockdown does not interfere with melanoma cells’
dissemination to the lung
We then tested whether the absence of TGFBI impairs the
dissemination of melanoma cells through a kinetic study of
micro-metastases formation in the lung. Mice received intra-
venous injection of CTRL- or TGFBI-shRNA-1205Lu cells at
day 0. Groups of five mice were euthanized at different time
points, and the lungs were analyzed for micro-metastases
development. We took advantage of GFP expression (Supple-
mentary Figure S1a online) to analyze the whole-lung cell
suspensions by flow cytometry. Although, we did not reach
significance, extravasation to the lung was detected as early as
24 hours post challenge with TGFBI-shRNA-1205Lu cells
(mean of 0.02% GFPþ cells in total lung) while it was detected
only on day 3 with CTRL-shRNA-1205Lu cells (Figure 3a).
The percentage of CTRL-shRNA-1205Lu extravasating cells
at day 5 remained similar to that at day 3, but a considerable
decline in the percentage (from mean of 0.08 to 0.037%) of
TGFBI-shRNA-1205Lu extravasating cells was observed after
5 days, and we could barely detect any GFPþ cells after
7 days. On the contrary, increasing numbers of GFPþ CTRL-
shRNA-1205Lu cells were detected over time, reaching a
mean of 0.4% by day 9. High-resolution two-photon micro-
scopy analyzing the localization of melanoma cells to the lung
corroborated with flow cytometry analysis (Figure 3b). Hema-
tological dissemination of melanoma cells to the lung was
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clearly visible as single-cell micro-metastasis 5 days after
implantation with both melanoma cell lines. However, by 9
days post implantation, several foci of larger metastases were
detected only in the CTRL-shRNA-1205Lu group, whereas
almost no GFPþ cells were present in the TGFBI-shRNA
group (Figure 3b).
Therefore, we investigated the role of TGFBI knockdown
in cell migration, invasion, extravasation, and adhesion
capacity in vitro. We found that TGFBI-shRNA-1205Lu
cells not only have higher migration than CTRL-shRNA-
1205Lu or wild-type (WT) 1205Lu cells (3.5-fold increase)
(Supplementary Figure S2a online) but also higher capacity
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Figure 1. Human melanoma produces large amounts of transforming growth factor beta (TGFb)-induced protein (TGFBI). (a) Expression of TGFBI mRNA
relative to PPIA housekeeping gene mRNA in benign nevi, primary skin, and metastatic melanomas. Median values are 0.50±0.087 (nevi), 1.15±0.28
(primary skin), and 3.82±0.28 (metastatic melanoma). (b) Representative images of TGFBI staining and quantification (right panel) in nine nevi (1 and 2), five
primary skin melanoma (primary), and in five skin, five liver, five lymph node (LN) metastases. Bar¼ 50mM. Mean values ±SEM are presented. (c) Secretion
of TGFBI by primary (WM293A, WM793) and their respective metastatic (WM983B, 1205Lu) melanoma cell lines. Results are expressed as mean values±SD of
TGFBI (pg) secreted by 1,000 cells from three independent experiments performed in triplicate. *Po0.05, **Po0.01, ***Po0.001. NS, not significant.
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to invade (2.5-fold increase) (Figure 3c left panel and
Supplementary Figure S2b online) and extravasate through
endothelial cells (2-fold increase) (Supplementary Figure S2c
online). TGFBI-shRNA-1205Lu cells also displayed higher
capacity to adhere than WT and CTRL-shRNA-1205Lu cells
(1.5-fold increase) (Figure 3c right panel and Supplementary
Figure S2d). The addition of recombinant TGFBI restored
invasion and adhesion to the level of WT cells (Figure 3c
and Supplementary Figure S3 online), indicating that the
observed increases are linked to the knockdown of TGFBI
secretion in TGFBI-shRNA-1205Lu cells. Similar results
were obtained when assays were conducted with cells
engineered with a second TGFBI-shRNA (Supplementary
Figures S2 and S3 online).
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Figure 2. Transforming growth factor beta (TGFb)-induced protein (TGFBI) expression is required for metastatic outgrowth. Nude mice received either
CTRL- or TGFBI-shRNA-1205Lu melanoma cells. (a) Body weight analysis at 3 weeks post-tumor inoculation. (b) Kaplan–Meier disease-free survival curves.
(c) Hematoxylin and eosin (H&E) staining of proximal and distal tissues indicating metastases formation (Tumor) and normal adjacent tissue (AT). Dashed lines
delineate tumor tissue border from normal AT. Bar¼ 50mm. Arrowheads point to mitotic figures. (d) H&E staining and quantification of frequently observed mitotic
figures in proximal metastases taken with  400 objectives. Each data point represents the average count of mitotic figures in 10 fields. Median (horizontal line) is
shown. (e) Representative TGFBI expression (left panel) and quantification (right panel) in different tissues ( 200 magnification). Mean values ±SEM are
presented. *Po0.05, **Po0.01, ***Po0.001.
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Collectively, these in vivo and in vitro findings show that
TGFBI-shRNA-1205Lu cells can extravasate like CTRL-
shRNA-1205Lu cells, but their survival is impeded in a new
microenvironment.
TGFBI is required for melanoma cells’ proliferation and survival
We then investigated the role of TGFBI in tumor cell
engraftment, namely cell growth and survival. Immunohisto-
chemical analyses showed that while CTRL-shRNA-induced
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Figure 3. Transforming growth factor beta (TGFb)-induced protein (TGFBI) silencing does not affect dissemination capacity of melanoma cells. (a) GFPþ
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**Po0.01, ***Po0.001.
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tumors display intense staining of cellular proliferation marker
Ki67, TGFBI-shRNA-induced tumors display reduced numbers
of Ki67þ -proliferating cells (Figure 4a). Accordingly, we
evaluated the effects of TGFBI knockdown on melanoma cells
growth in vitro. Proliferation of TGFBI-shRNA-1205Lu cells
was slower compared with WT and CTRL-shRNA-1205Lu
cells (Figure 4b). Notably TGFBI-shRNA-1205Lu cells showed
a drastic decline in their growth beginning at day 4 and
demonstrated the lowest rate of proliferation by day 6 (10-
folds less than WT and CTRL-shRNA-1205Lu cells). Mela-
noma cells engineered with another TGFBI-shRNA displayed
similar proliferation profile (Supplementary Figure S2e online).
7-Aminoactinomycin D (7-AAD)/Annexin-V staining showed
that only 20% of TGFBI-shRNA-1205Lu cells survived after 4
days of culture compared with 90% of CTRL-shRNA-1205Lu
cells (Figure 4c). Culturing TGFBI-shRNA-1205Lu cells in the
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Figure 4. Transforming growth factor beta (TGFb)-induced protein (TGFBI)-shRNA-1205Lu cells display lower proliferation rate and decreased survival.
(a) Representative images (left panel) and quantification (right panel) of Ki67 expression in CTRL- (n¼ 10) and TGFBI-shRNA-1205Lu (n¼ 9) proximal tumors
performed using 3DHISTECH panoramic slide viewer. Bar¼50mM. (b) Proliferation of wild-type (WT), CTRL- and TGFBI-shRNA-1205Lu cells was determined at
indicated time points. Results are presented as mean values±SD of absorbance from three independent experiments performed in triplicates. (c) Apoptosis and
survival of TGFBI-shRNA-1205Lu cells. Conditioned medium (CM) from CTRL-shRNA-1205Lu or anti-TGFBI-blocking antibody was added. Representative
dot-plot showing the percentage of cells in each quatrain (left panel), and the percentage of 7-AADnegAnnexinneg cells presented as mean values±SD from
three independent experiments (right panel). ***Po0.001. BrdU, 5-bromo-2’-deoxy-uridine; PE, phycoerythrin; 7-AAD, 7-aminoactinomycin D.
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presence of conditioned medium from CTRL-shRNA-1205Lu
cultures increased the percentage of living TGFBI-shRNA-
1205Lu cells to 70%, and the presence of a blocking anti-
TGFBI antibody completely abrogated this rescue (Figure 4c).
Thus, secretion of TGFBI contributes to melanoma cells’
growth and survival within their microenvironment.
Melanoma cells lacking TGFBI have defective cell cycle
progression
As the successful division and replication of cells is essential
for their survival, we examined the progression in cell cycle of
CTRL-shRNA-1205Lu cells in comparison to TGFBI-shRNA-
1205Lu over 5 days (Figure 5a and b). On day 1 TGFBI-
shRNA-1205Lu cells tend to increase their G0/G1 phase
(P¼ 0.08) and significantly decreased G2/M phases popula-
tions (P¼0.03) compared with CTRL-shRNA-1205Lu cells.
On day 2, TGFBI-shRNA-1205Lu cells showed significantly
decreased G0/G1 and G2/M phases (P¼ 0.01 and P¼ 0.006,
respectively) compared with CTRL-shRNA-1205Lu cells,
whereas the percentage of cells in S phase increased without
reaching significance. This is likely due to the emergence of
a subG1 phase population (15% apoptotic cells), while
CTRL-shRNA-1205Lu cells did not show any apoptotic cells
on day 2. At the end of the culture, G0/G1, S, and G2/M phase
populations presented, respectively, nearly 71, 13, and 10% in
CTRL-shRNA-1205Lu cultures compared with 44, 5 and 3% in
TGFBI-shRNA-1205Lu cultures (P¼0.0001, P¼0.007, and
P¼0.02, respectively). Nearly 6% of cell death was observed
in CTRL-shRNA-1205Lu cultures compared with 48% in
TGFBI-shRNA-1205Lu cultures. These results indicate that
TGFBI-shRNA-1205Lu cells have disturbed cell cycle progres-
sion likely with defects in G1/S transition and S phase
regulation. Therefore, we analyzed the expression of the
cyclin-dependent kinases (CDKs) and their regulators the
cyclins (CCN). Quantitative reverse transcriptase–PCR (RT-
PCR) analysis showed that TGFBI-shRNA-1205Lu cells express
extremely low levels of CDK2 and significantly lower level of
CDK6 compared with CTRL-shRNA-1205Lu cells (Figure 5c).
TGFBI-shRNA-1205Lu cells also expressed very low levels of
both CCNA and CCNE compared with CTRL-shRNA-1205Lu
cells (Figure 5d). CCNE/CDK2 complex activity is required for
G1/S transition. CCNA regulates two different phases, S and
M, in function of whether it binds to CDK2 or CDK1,
respectively. CDK6 is a catalytic subunit of the complex
CCND1/CDK6 that is important for cell cycle G1 phase
progression and G1/S transition.
Together, these results indicate that the secretion of TGFBI
by melanoma cells is likely implicated in maintaining the
expression of key regulators of their cell cycle and in the
regulation of melanoma metastatic outgrowth.
DISCUSSION
Through a knockdown approach and in vivo metastasis
model, we demonstrate the implication of TGFBI in mela-
noma distal metastasis formation through regulation of mela-
noma cells growth.
We found that TGFBI is expressed in nevus and melanoma
clinical specimens. However, it was more abundant, although
with a scattered pattern, in metastatic melanoma tissues.
Metastatic melanoma cell lines also secreted higher amounts
of TGFBI compared with their primary counterparts. Thus the
expression of TGFBI in melanoma is proportional to tumor
progression stage and aggressiveness. Melanoma tumors are
marked by their extensive heterogeneity (Fidler and Kripke,
1977; Banerjee and Harris, 2000), and specific transcriptional
signatures delineate various melanoma cells subpopulations
(Haqq et al., 2005; Hoek et al., 2006). In vivo, these specific
transcriptional signatures are linked and reversible given
appropriate signals and microenvironment cues, suggesting
that melanoma progression is associated with transcription
signature plasticity (Hoek et al., 2008). Heterogeneity and
plasticity could explain the scattered pattern of TGFBI by
different metastatic melanoma clinical specimens. In this
perspective, our findings endorse the expression of TGFBI by
melanoma as part of their plasticity towards aggressive
metastatic phenotype. Our in vivo studies in a model of
metastasis strongly support this notion. We found that the lack
of TGFBI not only reduces tumor incidence but also distant
metastases. That the secretion of TGFBI by melanoma cells
promotes their development and permits their metastatic
outgrowth suggests that TGFBI is part of the tumor-induced
ECM modifications allowing progression and dissemination.
In ovarian cancer, TGFBI production by peritoneal cells
promotes motility/invasion and adhesion of cancer cells to
peritoneal cells increasing their metastatic potential (Ween
et al., 2011). Human colon cancer cells lacking TGFBI have
decreased capacity to extravasate and decreased metastatic
potential (Ma et al., 2008). In our melanoma model, TGFBI
knockdown increases the capacity of tumor cells to migrate/
invade/extravasate and does not affect their dissemination
capacity in vivo. This is in line with TGFBI being an anti-
adhesive protein for melanoma cells (Nummela et al., 2012) and
indicates that TGFBI in melanoma potentiates metastases in a
manner distinct from that operating in other tumors. One
possible mechanism by which TGFBI affects cell adhesion and
migration is through its negative effect on cytoskeleton
dynamics. Downregulation of TGBFI in melanoma cells results
in increased co-localization of actin filaments, b1 integrins, and
talin (Nummela et al., 2012). TGFBI also stabilizes microtubules
(Ahmed et al., 2007), which could also affect the migration
process, and TGFBI silencing would favor microtubule
dynamics and thereby cell motility and invasion. The lack of
TGFBI resulted in a drastic decrease in the capacity of
melanoma cells to proliferate to form micro-metastases. In
line, we show that TGFBI produced from melanoma cells is
critical for their proliferation, and their growth inhibition and
defects in cell cycle progression were concomitant with drastic
cell death. This finding suggests that the drastic decrease in cell
proliferation observed in vivo is likely due to extensive cell
death in the absence of secreted TGFBI. This indicates that even
if melanoma cells lacking TGFBI have increased motility/
invasion/extravasation, their establishment, survival, and
growth within a new microenvironment, which is part of the
overall metastatic process, is impaired.
If TGFBI produced from melanoma cells is functionally
linked to their own growth and survival in distal metastases,
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how does it operate? Our rescue experiments in which shRNA
effect was reversed by exogenous TGFBI in conditioned
medium or recombinant TGFBI indicate that TGFBI released
by melanoma cells, rather than an intracellular form, likely
regulates their proliferation and survival. Actions of secreted
TGFBI depend on interactions between other ECM proteins
and specific integrins present in tumor microenvironment.
Growth and survival of melanoma cells through integrins is
regulated by the composition and the physical nature of the
ECM proteins (Petitclerc et al., 1999; Henriet et al., 2000).
Beside tumor-derived proteases, tumor-secreted ECM proteins
can also have critical roles in ECM modification/re-
organization to promote growth and survival (Berking et al.,
2001; Botti et al., 2012). Thus TGFBI upon its secretion by
melanoma cells could also be an actor of ECM remodeling
and re-organization providing a supporting scaffolding and a
positive feedback stimulation of tumor growth/survival. This
could be supported by the capacity of TGFBI to bind to several
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ECM proteins, including collagens, fibronectin, proteoglycans,
and periostin (Thapa et al., 2007), and its localization within
fibrillar fibronectin structures in melanoma tumors (Nummela
et al., 2012).
TGFBI knockdown induced growth inhibition through
defects in G1/S transition and S phase regulation by control-
ling the expression of CDK2 and CDK6 and their regulators
CCNA and CCNE. Regulation of CCNs requires coordinated
signaling from soluble factors and ECM/integrins. The signal-
ing pathways activated upon TGFBI/integrins interactions are
not yet fully determined, and we did not investigate the
signaling pathways supported by TGFBI in melanoma or the
implicated integrin. However, as part of intracellular signaling,
TGFBI interaction with integrins supports actin stress fiber
formation in adhering cells (Billings et al., 2002),
phosphorylation of AKT, extracellular signal–regulated kinase,
focal adhesion kinase, and paxillin in U87 and vascular
smooth cells (Kim et al., 2003; Lee et al., 2006), and
activation of phosphatidylinositol 30-kinase pathway in
keratinocytes (Oh et al., 2005).
TGFBI was originally identified as a TGFb-inducible gene
(Thapa et al., 2007). As increased TGFb expression was
correlated with melanoma progression and implicated in
promoting aggressiveness and metastasis (Javelaud et al.,
2008), it is possible that TGFBI acts among the effectors in
mediating the prometastatic/metastatic activity of TGFb in
these tumors. In breast cancer, a link between TGFb signaling,
TGFBI expression, and metastasis was proposed (Shipitsin
et al., 2007). In human melanomas, two populations with
very distinct gene expression profiles were identified: neural
crest and melanocytic differentiation phenotype and more
aggressive phenotype displaying a TGFb signature (Hoek
et al., 2006; Hoek, 2007; Hoek et al., 2008). TGFb has
anti-proliferative effects on normal melanocytes, whereas
melanoma cells display increased resistance to TGFb-
dependent growth inhibition, proportional to tumor
progression stage (Krasagakis et al., 1998) and is
probably highly specific to cell cycle progression (Rodeck
et al., 1999; Reed et al., 2001; Poser et al., 2005). Our
results demonstrate that the lack of TGFBI decreases the
expression of CDK2 and CCNE, thus CDK2/CCNE complex,
which binds to p21 inhibiting its activity and promoting
cell cycle progression. Therefore, we propose the abundance
of TGFBI in metastatic melanoma among the mechanisms
mediating the desensitization of aggressive melanoma
cells to TGFb anti-proliferative effect and suggest a link
between TGFb signaling, TGFBI expression, and melanoma
metastatic growth.
In summary, we describe a mechanism of melanoma
metastatic outgrowth via promotion of growth/survival by
TGFBI. The management of melanoma metastatic
outgrowth remains a clinical challenge, and elevated
secretion of TGFBI could be used as a biomarker for indicating
patients with progressing tumors. Although this warrant
further investigations, TGFBI being an ECM protein,
peptides or antibodies that inhibit or limit its action
might be among the strategies to control or limit melanoma
metastases.
MATERIALS AND METHODS
Patient samples and melanoma cell cultures
Frozen human nevus (n¼ 6), primary skin melanoma (n¼ 5), and
metastatic melanoma (n¼ 20) specimens (Saint Louis Hospital,
Dermatology Department, Paris, France) were used for RNA extrac-
tion. Paraffin blocks of human nevus (n¼ 9), primary skin melanoma
(5), and skin (n¼ 5), lymph node (n¼ 5), and liver (n¼ 5) metastatic
melanomas were obtained from the laboratory of anatomy and
pathological cytology (Purpan Hospital, Toulouse, France). Speci-
mens were collected, and the study was performed according to the
guidelines of Hospitals institutional boards and Ethic Committees after
written informed patients’ consent, in accordance with the Helsinki
Declaration. Human melanoma cell lines (gift from Alain Mauviel
(Curie Institute, Orsay, France)) derived from tumor biopsies from
patients with primary (WM983A and WM793) or metastatic
(WM983B and 1205Lu) melanoma lesions (Alexaki et al., 2010)
were grown in DMEM/F-12 medium supplemented with 10% fetal
calf serum (Invitrogen, Saint Aubin, France).
Stable TGFBI silencing in 1205Lu human melanoma cells
Stably transduced cells were generated by lentiviral infection
using pLKO.1-puro-CMV-TurboGFP plasmid (Sigma-Aldrich,
Saint-Quentin Fallavier, France) encoding non-targeting shRNA
(CTRL-shRNA, Sigma-Aldrich SHC002V) or shRNA targeting the
coding sequence of TGFBI (TGFBI-shRNA clone TRCN0000062174
and TRCN0000062175). RT-PCR and ELISA verified stable
reduction of TGFBI mRNA expression and TGFBI secretion over
time. Detailed procedures are described under Supplementary
Information online.
Gene expression
Total mRNA was isolated using RNeasy kit (Qiagen, Valenica, CA)
and reverse transcribed with Omniscript (Qiagen). cDNAs were then
processed for RT-PCR using SYBR Green PCR kit (Applied Biosystems,
Villebon-sur-Yvette, France). Gene-specific primers are summarized
in Supplementary Table S1 online, and technical details are under
Supplementary Information online.
Experimental metastasis in mice
Six to 8-week-old female nude mice (NMRI Nu/Nu) were injected into
the retro-orbital venous sinus with 5 105 melanoma cells expressing
CTRL-shRNA or TGFBI-shRNA as described (Galaup et al., 2006).
Mice were monitored twice a week to detect weakness, weight loss, or
morbidity, and those losing 415% of their weight were euthanized.
Spleen, lymph nodes, liver, lung, kidney, colon, ovary, and uterus
were removed and processed for histopathological analysis as
described (Chabot et al., 2011). All animal experiments were
performed in agreement with the European Union guidelines and
approved by the local Ethic Committee (MP/02/37/06/08).
Histopathology and immunostaining
Formalin-fixed paraffin-embedded specimens of melanoma tissues
were processed for hematoxylin/eosin staining or immunohistochem-
istry. Immunohistochemistry were performed with anti-TGFBI (Pro-
teintech, Manchester, UK) or anti-Ki67 (Thermo Scientific,
Courtaboeuf, France) mAbs, revealed using the ABC-peroxidase kit
(Vector Laboratories, Peterborough, UK), analyzed with a Leica DMR
microscope (Leica Microsystems, Nanterre, France) at  200
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objective, and specific pixel intensities over field area were calculated
in mm2 using 3DHISTECH panoramic slide viewer (3DHISTECH Kft,
Budapest, Hungary). Details are under Supplementary Information
online.
Two-photon microscopy and second-harmonic generation
Lungs were removed, fixed in 3% formaldehyde, and tissues were
mounted using surgical glue. Images were taken on a Zeiss inverted
two-photon microscope ( 20 water-immersion objective) (Carl
Zeiss, Jena, Germany). Helical structures of collagen fibers were
imaged using the second-harmonic generation structures. The appear-
ance of lung metastases was followed using GFP. Z-stack images
were collected over 250-mm deep sections.
Proliferation, apoptosis, and cell cycle assays
CTRL- and TGFBI-shRNA-1205Lu cells were grown as indicated, and
proliferation, apoptosis, and cell cycle were analyzed. Proliferation
was evaluated using 5-bromo-2’-deoxy-uridine labeling and detection
kit III (Roche, Boulogne-Billancourt, France) by absorbance measure-
ment at 405 nm. Apoptosis was determined using 7-AAD and
Annexin-V–phycoerythrin (BD Biosciences, Le Pont-de-Claix, France)
staining and flow cytometry (FACS Canto II) analysis (BD Bios-
ciences). Supernatant from CTRL-shRNA-1205Lu cultures was used
to replace that of TGFBI-shRNA-1205Lu cultures in the presence or
absence of an anti-TGFBI-blocking antibody (Proteintech). Cell cycle
was analyzed on fixed cells and stained using propidium iodide
supplemented with RNAse A (Sigma-Aldrich). DNA contents were
analyzed on a FACS Calibur cytometer (BD Biosciences). Percentages
of cells in G0/G1, S, and G2/M phases were determined by Watson
method using the FlowJo software (Celeza, Olten, Switzerland).
Migration, matrigel invasion, and extravasation assays
CTRL- and TGFBI-shRNA-1205Lu cells were harvested, re-suspended
in serum-free medium (Miltenyi Biotech, Bergisch Gladbach, Germany)
with or without soluble recombinant TGFBI (100 nM) (R&D Systems,
Lille, France) and seeded at 5 104 cell on Transwell inserts coated
or not with growth-factor reduced Matrigel (BD Bioscience). After
6 hours, migrating/invading cells were fixed, stained, and counted
under a light microscope. Extravasation assays were conducted
following the above procedure but using fluoroblok transwell inserts
coated with matrigel and human microvascular endothelial cells
seeded at 5 104 cell/well, and DiO-labeled extravasading mela-
noma cells were directly counted using fluorescence microscopy.
Details are under Supplementary Information online.
Adhesion assays
CTRL- and TGFBI-shRNA-1205Lu melanoma cells were harvested, re-
suspended in serum-free medium with 0.1% BSA, seeded in a 96-well
plate at 2.5 104 cell/well, and allowed to adhere for 1 hour. Cells
were then fixed with 1% formaldehyde, stained with violet cristal,
then lysed with 1% SDS, and absorbance at 600 nm using a
microplate reader determined the relative adherence.
Statistical analyses
For TGFBI gene expression, migration/invasion/extravasation, and pro-
liferation assays, we used the t test to calculate 95% confidence intervals
on differences between median or mean and Mann–Whitney test to
obtain P value. Data related to experimental metastasis in mice were
analyzed using two-way analysis of variance test. All statistical tests
were two-sided. Po0.05 was considered to be statistically significant.
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